152 related articles for article (PubMed ID: 18949742)
1. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.
Decock J; Obermajer N; Vozelj S; Hendrickx W; Paridaens R; Kos J
Int J Biol Markers; 2008; 23(3):161-8. PubMed ID: 18949742
[TBL] [Abstract][Full Text] [Related]
2. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I
Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K
Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098
[TBL] [Abstract][Full Text] [Related]
4. Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera.
Cimerman N; Brguljan PM; Krasovec M; Suskovic S; Kos J
Clin Chim Acta; 1999 Apr; 282(1-2):211-8. PubMed ID: 10340450
[No Abstract] [Full Text] [Related]
5. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
6. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
[TBL] [Abstract][Full Text] [Related]
7. Serum cysteine proteases and their inhibitors in rheumatoid arthritis: relation to disease activity and radiographic progression.
Jørgensen I; Kos J; Krašovec M; Troelsen L; Klarlund M; Jensen TW; Hansen MS; Jacobsen S; ;
Clin Rheumatol; 2011 May; 30(5):633-8. PubMed ID: 20924627
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications.
Leto G; Tumminello FM; Pizzolanti G; Montalto G; Soresi M; Gebbia N
Oncology; 1997; 54(1):79-83. PubMed ID: 8978598
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors.
Kawasaki G; Kato Y; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284
[TBL] [Abstract][Full Text] [Related]
10. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
Schweiger A; Christensen IJ; Nielsen HJ; Sørensen S; Brünner N; Kos J
Int J Biol Markers; 2004; 19(4):289-94. PubMed ID: 15646835
[TBL] [Abstract][Full Text] [Related]
11. Serum concentration and circadian profiles of cathepsins B, H and L, and their inhibitors, stefins A and B, in asthma.
Cimerman N; Mesko Brguljan P; Krasovec M; Suskovic S; Kos J
Clin Chim Acta; 2001 Aug; 310(2):113-22. PubMed ID: 11498076
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis.
Nagai A; Terashima M; Harada T; Shimode K; Takeuchi H; Murakawa Y; Nagasaki M; Nakano A; Kobayashi S
Clin Chim Acta; 2003 Mar; 329(1-2):53-60. PubMed ID: 12589965
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of detection of cathepsin X and cystatin C in the sera of patients with lung cancer].
Zhang X; Hou Y; Niu Z; Li W; Meng X; Zhang N; Yang S
Zhongguo Fei Ai Za Zhi; 2013 Aug; 16(8):411-6. PubMed ID: 23945244
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
[TBL] [Abstract][Full Text] [Related]
15. Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.
Gabrijelcic D; Annan-Prah A; Rodic B; Rozman B; Cotic V; Turk V
J Clin Chem Clin Biochem; 1990 Mar; 28(3):149-53. PubMed ID: 2329322
[TBL] [Abstract][Full Text] [Related]
16. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
[TBL] [Abstract][Full Text] [Related]
17. Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.
Hansen T; Petrow PK; Gaumann A; Keyszer GM; Otto M; Kirkpatrick CJ; Kriegsmann J
Mod Pathol; 2001 Apr; 14(4):318-24. PubMed ID: 11301348
[TBL] [Abstract][Full Text] [Related]
18. Cystatin C and cysteine proteinases during the development and therapy of Lewis lung adenocarcinoma in mice.
Usova TA; Poteryaeva ON; Zhanayeva SY; Yarygina ES; Korolenko TA
Bull Exp Biol Med; 2003 Jan; 135(1):81-4. PubMed ID: 12717521
[TBL] [Abstract][Full Text] [Related]
19. Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of cholangiocarcinoma.
Monsouvanh A; Proungvitaya T; Limpaiboon T; Wongkham C; Wongkham S; Luvira V; Proungvitaya S
Asian Pac J Cancer Prev; 2014; 15(21):9511-5. PubMed ID: 25422248
[TBL] [Abstract][Full Text] [Related]
20. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
Trinkaus M; Vranic A; Dolenc VV; Lah TT
Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
